Cardiovascular disease and cancer: shared risk factors and mechanisms

NS Wilcox, U Amit, JB Reibel, E Berlin… - Nature Reviews …, 2024‏ - nature.com
Cardiovascular disease (CVD) and cancer are among the leading causes of morbidity and
mortality globally, and these conditions are increasingly recognized to be fundamentally …

Cardiotoxicity of anticancer drugs: molecular mechanisms, clinical management and innovative treatment

F Gao, T Xu, F Zang, Y Luo, D Pan - Drug Design, Development …, 2024‏ - Taylor & Francis
With the continuous refinement of therapeutic measures, the survival rate of tumor patients
has been improving year by year, while cardiovascular complications related to cancer …

Cardiovascular Considerations Before Cancer Therapy: Gaps in Evidence and JACC: CardioOncology Expert Panel Recommendations

Z Raisi-Estabragh, AC Murphy, S Ramalingam… - Cardio Oncology, 2024‏ - jacc.org
Baseline cardiovascular assessment before the initiation of potentially cardiotoxic cancer
therapies is a key component of cardio-oncology, aiming to reduce cardiovascular …

Overcoming proteasome inhibitor resistance in the immunotherapy era

B Patiño-Escobar, A Talbot, AP Wiita - Trends in pharmacological sciences, 2023‏ - cell.com
Proteasome inhibitors (PIs) are a fascinating class of small molecules that disrupt protein
homeostasis and are highly efficacious in the blood cancer multiple myeloma. However, PIs …

Management of hypertension in patients with cancer: challenges and considerations

S Pandey, A Kalaria, KD Jhaveri… - Clinical kidney …, 2023‏ - academic.oup.com
The survival rates of many cancers have significantly improved due to recent advancements
in cancer screening and therapeutics. Although better cancer outcomes are encouraging …

[HTML][HTML] Drug-induced atrial fibrillation. A narrative review of a forgotten adverse effect

J Tamargo, J Villacastín, R Caballero… - Pharmacological …, 2024‏ - Elsevier
Atrial fibrillation (AF) is the most common cardiac arrhythmia and is associated with an
increased morbidity and mortality. There is clinical evidence that an increasing number of …

Repurposing proteasome inhibitors for improved treatment of triple-negative breast cancer

P Larsson, D Pettersson, M Olsson… - Cell Death …, 2024‏ - nature.com
Triple-negative breast cancer (TNBC) is associated with poor prognosis and limited
treatment options due to the lack of important receptors (estrogen receptor [ER] …

Proteasome inhibitors related thrombotic microangiopathy: a systematic and comprehensive review

C Chen, Y Li, P Shi, S Qian - Blood Cancer Journal, 2024‏ - nature.com
Proteasome inhibitors (PIs) are crucial in treating multiple myeloma but carry a risk of
thrombotic microangiopathy (TMA), especially with carfilzomib use. This systematic review …

Characteristics and outcomes of patients develo** pulmonary hypertension associated with proteasome inhibitors

J Grynblat, C Khouri, A Hlavaty, X Jaïs… - European …, 2024‏ - publications.ersnet.org
Background Pulmonary arterial hypertension (PAH) has been described in patients treated
with proteasome inhibitors (PIs). Our objective was to evaluate the association between PIs …

Intercellular pathways of cancer treatment-related cardiotoxicity and their therapeutic implications: the paradigm of radiotherapy

S Logotheti, A Pavlopoulou, HK Rudsari… - Pharmacology & …, 2024‏ - Elsevier
Advances in cancer therapeutics have improved patient survival rates. However, cancer
survivors may suffer from adverse events either at the time of therapy or later in life …